Trials / Completed
CompletedNCT02026063
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telotristat etiprate | Telotristat etiprate tablet (250 mg) |
Timeline
- Start date
- 2014-01-14
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
- First posted
- 2014-01-01
- Last updated
- 2019-09-17
- Results posted
- 2019-09-17
Locations
43 sites across 12 countries: United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02026063. Inclusion in this directory is not an endorsement.